Alerts will be sent to your verified email
Verify EmailBLISSGVS
Bliss GVS Pharma
|
Jagsonpal Pharma
|
Syncom Formulations
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
2.7 % | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
6.83 % | 16.01 % | 8.81 % |
5yr average Equity Multiplier
|
1.3 | 1.27 | 1.5 |
5yr Average Asset Turnover Ratio
|
0.62 | 1.09 | 0.79 |
5yr Avg Net Profit Margin
|
8.7 % | 12.08 % | 7.78 % |
Price to Book
|
1.51 | 6.74 | 4.92 |
P/E
|
14.92 | 26.59 | 29.23 |
5yr Avg Cash Conversion Cycle
|
186.56 Days | 2.39 Days | 84.02 Days |
Inventory Days
|
54.35 Days | 37.29 Days | 27.61 Days |
Days Receivable
|
189.93 Days | 15.63 Days | 123.89 Days |
Days Payable
|
75.78 Days | 59.94 Days | 93.18 Days |
5yr Average Interest Coverage Ratio
|
14.68 | 66.99 | 39.83 |
5yr Avg ROCE
|
13.27 % | 18.99 % | 12.74 % |
5yr Avg Operating Profit Margin
|
17.03 % | 13.23 % | 9.47 % |
5 yr average Debt to Equity
|
0.11 | 0.01 | 0.2 |
5yr CAGR Net Profit
|
4.24 % | 26.54 % | 19.56 % |
5yr Average Return on Assets
|
5.31 % | 12.71 % | 5.89 % |
Shareholdings
|
|||
Promoter Holding
|
35.44 % | 67.65 % | 50.57 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.93 % | -1.06 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Bliss GVS Pharma
|
Jagsonpal Pharma
|
Syncom Formulations
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|